不同肿瘤标志物在卵巢癌筛查中的应用

摘要

目的 探寻卵巢癌诊断的理想肿瘤标志物,以提高卵巢癌筛查的准确性和灵敏度.方法 荧光定量PCR(FQ-PCR)检测测定20例卵巢良性变和85例卵巢癌患者基因突变型p53拷贝数,ELISA法检测血清中肿瘤相关抗原(CA125)、癌胚抗原(CEA)、恶性肿瘤特异性生长因子(TGSF).结果 CA125、CEA、肿瘤特异性生长因子(TSGF)和 p53,4种标志物的水平及阳性率明显高于良性组(P＜0.05),在几种组合中,CA125、TGSF、p53三者组合在Ⅰ、Ⅱ期卵巢癌中特异性达54.1%,灵敏度达88.5%.结论 CA125、TGSF和p53联合是卵巢癌筛查较好的组合.%Objective To explore the best tumor marker combination in diagnosis of early stage ovary cancer and to get higher accuracy and sensitivity. Methods Serum levels of CA125 , CEA and TGSF were detected by enzyme linked immunosorbent assay in 20 cases of benign o-vary diseases and 85 cases of ovary cancer. Meanwhile mutant genotype p53 was detected by FQ - PCR. Results The serum levels and positive rates of CA125 , CEA, TGSF and mutant p53 in patients with ovary cancers were significantly higher than those of patients with benign ovary tumor ( P <0.05). The combined detection of CA125 ,TGSF and mutant genotype p53 had higher positive rate ( 90. 8% ) than others in patients with I, Ⅱ stage ovary cancer. Conclusion The combined detection of CA125 , TGSF and p53 is an effective method for screening ovary cancer.